Cargando…
Target Validation and Identification of Novel Boronate Inhibitors of the Plasmodium falciparum Proteasome
[Image: see text] The Plasmodium proteasome represents a potential antimalarial drug target for compounds with activity against multiple life cycle stages. We screened a library of human proteasome inhibitors (peptidyl boronic acids) and compared activities against purified P. falciparum and human 2...
Autores principales: | Xie, Stanley C., Gillett, David L., Spillman, Natalie J., Tsu, Christopher, Luth, Madeline R., Ottilie, Sabine, Duffy, Sandra, Gould, Alexandra E., Hales, Paul, Seager, Benjamin A., Charron, Carlie L., Bruzzese, Frank, Yang, Xiaofeng, Zhao, Xiansi, Huang, Shih-Chung, Hutton, Craig A., Burrows, Jeremy N., Winzeler, Elizabeth A., Avery, Vicky M., Dick, Lawrence R., Tilley, Leann |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2018
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257627/ https://www.ncbi.nlm.nih.gov/pubmed/30373366 http://dx.doi.org/10.1021/acs.jmedchem.8b01161 |
Ejemplares similares
-
Using in Vitro Evolution and Whole
Genome Analysis To Discover Next Generation Targets for Antimalarial Drug Discovery
por: Luth, Madeline R., et al.
Publicado: (2018) -
The proteasome as a target: How not tidying up can have toxic consequences for parasitic protozoa
por: Winzeler, Elizabeth A., et al.
Publicado: (2019) -
Artemisinin kills malaria parasites by damaging proteins and inhibiting the proteasome
por: Bridgford, Jessica L., et al.
Publicado: (2018) -
Design of proteasome inhibitors with oral efficacy in vivo against Plasmodium falciparum and selectivity over the human proteasome
por: Xie, Stanley C., et al.
Publicado: (2021) -
Covalent Plasmodium falciparum-selective proteasome inhibitors exhibit a low propensity for generating resistance in vitro and synergize with multiple antimalarial agents
por: Stokes, Barbara H., et al.
Publicado: (2019)